Meta-analysis of the association between P53 codon 72 polymorphisms and gastric cancer

Journal of Surgical Oncology

Volumn 107, Issue 4, 2013, Pages 360-366

  Zhang, Qi ^a   Ma, Ying Yu ^b   Wang, Hui Ju ^b   Shao, Chang Ming ^a   Zhang, Jun ^a   Ye, Zai Yuan ^a,b  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b Key Laboratory of Gastroenterology   (China)

Author keywords

gastric cancer; P53; polymorphisms

Indexed keywords

PROTEIN P53;

ALLELE; APOPTOSIS; ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; CELL CYCLE ARREST; CODON; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENOTYPE; HUMAN; PRIORITY JOURNAL; STOMACH CANCER; SYSTEMATIC REVIEW;

ARGININE; ASIAN CONTINENTAL ANCESTRY GROUP; CODON; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROLINE; RISK FACTORS; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84874276355     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23233     Document Type: Article

References (62)

1. De Feo E, Persiani R, La Greca A, et al.: A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. Mutat Res 2009; 675: 60-65.
2. Parkin DM, Bray F, Ferlay J, et al.: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. Zhao ZS, Wang YY, Chu YQ, et al.: SPARC is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2010; 16: 260-268.
4. Inoue M, Tsugane S:, Epidemiology of gastric cancer in Japan. Postgrad Med J 2005; 81: 419-424.
5. Luo Z, Zhang Q, Zhao Z, et al.: OLFM4 is associated with lymph node metastasis and poor prognosis in patients with gastric cancer. J Cancer Res Clin Oncol 2011; 137: 1713-1720.
6. Li W, Yu CP, Xia JT, et al.: Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2009; 15: 1393-1399.
7. Yasui W, Oue N, Kuniyasu H, et al.: Molecular diagnosis of gastric cancer: Present and future. Gastric Cancer 2001; 4: 113-121.
8. Feinberg AP, Ohlsson R, Henikoff S:, The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21-33.
9. Zhu Y, Spitz MR, Amos CI, et al.: An evolutionary perspective on single-nucleotide polymorphism screening in molecular cancer epidemiology. Cancer Res 2004; 64: 2251-2257.
10. Pharoah PD, Dunning AM, Ponder BA, et al.: Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004; 4: 850-860.
11. Bond GL, Levine AJ:, A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. Oncogene 2007; 6: 1317-1323.
12. Orsted DD, Bojesen SE, Tybjaerg-Hansen A, et al.: Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. J Exp Med 2007; 204: 1295-1301.
13. Koushik A, Tranah GJ, Ma J, et al.: p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 2006; 119: 1863-1868.
14. Schabath MB, Wu X, Wei Q, et al.: Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006; 15: 158-161.
15. Ueda M, Terai Y, Kanda K, et al.: Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol 2006; 100: 173-178.
16. Kochethu G, Delgado J, Pepper C, et al.: Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia. Leuk Res 2006; 30: 1113-1118.
17. Rogler A, Rogenhofer M, Borchardt A, et al.: P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: Association between disease onset and proline genotype. Pathobiology 2011; 78: 193-200.
18. Sumbul AT, Akkiz H, Bayram S, et al.: p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: A case-control study. Mol Biol Rep 2012; 39: 1639-1647.
19. Dahiya R, Deng G, Chen KM, et al.: P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer. Br J Cancer 1996; 74: 264-268.
20. Chen WC, Tsai FJ, Wu JY, et al.: Distributions of p53 codon 72 polymorphism in bladder cancer-proline form is prominent in invasive tumor. Urol Res 2000; 28: 293-296.
21. Thomas M, Kalita A, Labrecque S, et al.: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19: 1092-1100.
22. Ke-Xiang Z, Yu-Min L, Xun L, et al.: Study on the association of p53 codon 72 polymorphisms with risk of gastric cancer in high incidence Hexi area of Gansu Province in China. Mol Biol Rep 2012; 39: 723-728.
23. Zhang ZW, Newcomb P, Hollowood A, et al.: Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res 2003; 9: 2151-2156.
24. Zhang ZW, Newcomb P, Hollowood A, et al.: A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: Roles of gastric mucosal histology and p53 codon 72 polymorphism. Dig Dis Sci 2004; 49: 254-259.
25. Shepherd T, Tolbert D, Benedetti J, et al.: Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology 2000; 118: 1039-1044.
26. Zhang ZW, Laurence NJ, Hollowood A, et al.: Prognostic value of TP53 codon 72 polymorphism in advanced gastric adenocarcinoma. Clin Cancer Res 2004; 10: 131-135.
27. Xi YG, Ding KY, Su XL, et al.: p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis 2004; 25: 2201-2206.
28. Khayat AS, Lobo GL, Moura LE, et al.: Polymorphisms of the TP53 codon 72 and WRN codon 1367 in individuals from Northern Brazil with gastric adenocarcinoma. Clin Exp Med 2005; 5: 161-168.
29. Hiyama T, Tanaka S, Kitadai Y, et al.: p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. Int J Cancer 2002; 100: 304-308.
30. Hamajima N, Matsuo K, Suzuki T, et al.: No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 2002; 181: 81-85.
31. Wu MT, Chen MC, Wu DC:, Influences of lifestyle habits and p53 codon 72 and p21 codon 31 polymorphisms on gastric cancer risk in Taiwan. Cancer Lett 2004; 205: 61-68.
32. Shen H, Solari A, Wang X, et al.: P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep 2004; 11: 1115-1120.
33. Perez-Perez GI, Bosques-Padilla FJ, Crosatti ML, et al.: Role of p53 codon 72 polymorphism in the risk of development of distal gastric cancer. Scand J Gastroenterol 2005; 40: 56-60.
34. Mu LN, Lu QY, Yu SZ, et al.: Green tea drinking and multigenetic index on the risk of stomach cancer in a Chinese population. Int J Cancer 2005; 116: 972-983.
35. Lai KC, Chen WC, Tsai FJ, et al.: Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. Hepatogastroenterology 2005; 52: 944-948.
36. Sul J, Yu GP, Lu QY, et al.: P53 Codon 72 polymorphisms: A case-control study of gastric cancer and potential interactions. Cancer Lett 2006; 238: 210-223.
37. Chung WC, Lee KM, Lee BI, et al.: P53 genetic polymorphism of gastric cancer in Korea. Korean J Intern Med 2006; 21: 28-32.
38. Belyavskaya VA, Vardosanidze VK, Smirnova OY, et al.: Genetic status of p53 in stomach cancer: Somatic mutations and polymorphism of codon 72. Bull Exp Biol Med 2006; 141: 243-246.
39. Yi SY, Lee WJ:, A p53 genetic polymorphism of gastric cancer: Difference between early gastric cancer and advanced gastric cancer. World J Gastroenterol 2006; 12: 6536-6539.
40. Ihsan R, Devi TR, Yadav DS, et al.: Investigation on the role of p53 codon 72 polymorphism and interactions withtobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol 2011; 30: 163-171.
41. Shirai O, Ohmiya N, Taguchi A, et al.: P53, p21, and p73 gene polymorphisms in gastric carcinoma. Hepatogastroenterology 2010; 57: 1595-1601.
42. Engin AB, Karahalil B, Karakaya AE, et al.: Association between XRCC1 ARG399GLN and P53 ARG72PRO polymorphisms and the risk of gastric and colorectal cancer in Turkish population. Arh Hig Rada Toksikol 2011; 62: 207-214.
43. Gomes de Souza L, Miranda de Lima J, Dale Cotrim Guerreiro da Silva I:, Manoukian Forones N l. P53 Arg72Pro polymorphism in gastric cancer patients. J Gastrointest Cancer 2009; 40: 41-45.
44. Yang M, Guo Y, Zhang X, et al.: Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 2007; 28: 1996-2001.
45. Song HR, Kweon SS, Kim HN, et al.: p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer 2011; 14: 242-248.
46. Kim N, Cho SI, Lee HS, et al.: The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea. Dig Dis Sci 2010; 55: 101-110.
47. Zhou Y, Li N, Zhuang W, et al.: P53 codon 72 polymorphism and gastric cancer: A meta-analysis of the literature. Int J Cancer 2007; 121: 1481-1486.
48. Lane DP:, Cancer, p53, guardian of the genome. Nature 1992; 358: 15-16.
49. Levine AJ:, p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
50. Malik MA, Sharma K, Goel S, et al.: Association of TP53 intron 3, 16 bp duplication polymorphism with esophageal and gastric cancer susceptibility in Kashmir Valley. Oncol Res 2011; 19: 165-169.
51. Millau JF, Bastien N, Drouin R:, P53 transcriptional activities: A general overview and some thoughts. Mutat Res 2009; 681: 118-133.
52. Klug SJ, Ressing M, Koenig J, et al.: TP53 codon 72 polymorphism and cervical cancer: A pooled analysis of individual data from 49 studies. Lancet Oncol 2009; 10: 772-784.
53. Li DB, Wei X, Jiang LH, et al.: Meta-analysis of epidemiological studies of association of P53 codon 72 polymorphism with bladder cancer. Genet Mol Res 2010; 9: 1599-1605.
54. Zhu ZZ, Liu B, Wang AZ, et al.: Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression. J Zhejiang Univ Sci B 2008; 9: 847-852.
55. Zhang R, Chen W, Zhang W, et al.: Genetic polymorphisms of p53 codon 72 and bladder cancer susceptibility: A hospital-based case-control study. Genet Test Mol Biomarkers 2011; 15: 337-341.
56. Huang SP, Wu WJ, Chang WS, et al.: p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 2217-2224.
57. Katkoori VR, Jia X, Shanmugam C, et al.: Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 2009; 15: 2406-2416.
58. Papadakis ED, Soulitzis N, Spandidos DA:, Association of p53 codon 72 polymorphism with advanced lung cancer: The Argallele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 2002; 87: 1013-1018.
59. Zhang Z, Wang M, Wu D, et al.: P53 codon 72 polymorphism contributes to breast cancer risk: A meta-analysis based on 39 case-control studies. Breast Cancer Res Treat 2010; 120: 509-517.
60. Yamashita T, Yaginuma Y, Saitoh Y, et al.: Codon 72 polymorphism of p53 as a risk factor for patients with human papilloma virus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix. Carcinogenesis 1999; 20: 1733-1736.
61. Petitjean A, Achatz MI, Borresen-Dale AL, et al.: TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-2165.
62. Koushik A, Platt RW, Franco EL:, p53 codon 72 polymorphism and cervical neoplasia: A meta-analysis review. Cancer Epidemiol Biomarkers Prev 2004; 13: 11-22.